Boston, MA -- (SBWIRE) -- 01/14/2014 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Riverbed Technology, Inc. (NASDAQ:RVBD), Oncolytics Biotech, Inc. (USA)(NASDAQ:ONCY), Oren Therapeutics, Inc.(NASDAQ:OREX).
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), opened its shares at the price of $3.95 for the day. Its closing price was $3.65 after losing -4.45% for the day. The company traded with the total volume of 3.07 million shares, while its average trading volume remained 2.15 million shares. The beta of ACHN stands at0.37. Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on the development of antivirals for the treatment of chronic hepatitis C viral (HCV) infection.
-Will ACHN Get Buyers Even After The Recent Rally? Find Out Here
Riverbed Technology, Inc. (NASDAQ:RVBD), percentage change plunged -0.65% to close at $19.79 with the total traded volume of 2.94 million shares, and average volume of 2.15 million. The 52 week range of the stock remained $13.77 - $20.74 Riverbed Technology, Inc. (Riverbed) has developed solutions to the fundamental problems associated with information technology (IT) performance across wide area networks (WANs). Riverbed’s family of performance products include solutions for branch offices, mobile workers, private data centers, private clouds and cloud computing.
Will RVBD Get Buyers Even After The Recent Rally? Find Out Here
Oncolytics Biotech, Inc. (USA)(NASDAQ:ONCY), started its trading session with the price of $1.70 and closed at $1.81 by scoring 9.04%. ONCY’s stocks traded with total volume of 2.94 million shares, while the average trading volume remained 434,639 shares. Oncolytics Biotech Inc. (Oncolytics) is a development-stage company. The Company is focused on its research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from the reovirus. This virus has been demonstrated in tumour cells bearing an activated Ras pathway. Will ONCY Continue To Move Higher? Find Out Here
Orexigen Therapeutics, Inc.(NASDAQ:OREX) ended its day with the loss of -4.25% and closed at the price of $6.09 after opening at $6.39. Stock traded during its last trading session with the total volume of 2.91 million shares, as compared to its average volume of 2.87 million shares. Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body's efforts to compensate for weight loss.
Will OREX Get Buyers Even After The Recent Rally? Find Out Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t be disappointed.
http://winstonsmallcap.com/ and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)